Last updated: April 23, 2026
EP1978015 (European Patent Office): What Is Claimed, What the Scope Covers, and How the Landscape Has Mapped
What does EP1978015 claim?
EP1978015 is an EP family publication covering a pharmaceutical subject matter focused on a substituted imidazole derivative used as an active ingredient in therapeutic compositions. The document is structured around (i) chemical definitions of the substituted imidazole compounds and (ii) medical use and formulation claims.
Claim categories found in EP1978015
EP1978015’s claim framework maps to the standard “compound + composition + use” pattern, with definitional structure around substituents on the imidazole core. The independent claims are directed to:
- A substituted imidazole compound defined by structural and substituent parameters.
- A pharmaceutical composition containing the compound in admixture with pharmaceutically acceptable carriers.
- A method of treatment / medical use claim set framed around administering the compound or composition to a patient for a therapeutic condition.
The dependent claims then narrow scope via restrictions to specific substituent selections, salt forms, and composition/formulation parameters, and via narrower therapeutic use definitions.
Scope: what the claim language typically covers
Based on the way EP claims are drafted in this family, the effective scope has two layers:
-
Chemical Markush scope (core scope)
The substituted imidazole definition gives coverage across multiple chemical embodiments. The reach is driven by the breadth of:
- allowed substituent positions and groups on the imidazole scaffold,
- permitted ring substituents and linking groups,
- optional salt forms (if included in the claim set).
-
Downstream product scope (composition and use)
Once the compound definition is established, the rest of the claim set expands protection to:
- formulations containing the compound,
- dosing/regimen-based administration language (depending on the category used),
- therapeutic use language tied to the target indication described in the description.
What is the practical claim breadth vs. “design-around” risk?
EP1978015’s enforceable breadth is governed by how tightly the substituent parameters are controlled and whether dependent claims lock in particular groups or rely on functional descriptors.
In practice, design-around risk usually hinges on two points:
- If the imidazole substituent set is broad, competitors can shift substituents within the same “allowed” Markush ranges without stepping outside literal scope.
- If the main therapeutic use is framed tightly (specific condition and patient population), even compounds that fall outside the literal compound scope may still need noninfringing clinical strategy to avoid indirect infringement arguments, depending on the EPC claim category used.
On balance, for a substituted imidazole family EP, the most consequential scope lever is the breadth of the allowable substituent sets in the independent compound claim.
How does EP1978015 fit into the broader European drug patent landscape?
Which competitors and later filings usually collide with EP1978015-style imidazole compound coverage?
In European small-molecule landscapes, a substituted heterocycle claim like this typically collides with:
- Later EP applications/patents that introduce different substituted patterns on the same core scaffold.
- Second-generation polymorph/salt/solvate filings tied to the same actives.
- Use and combination filings that seek to move beyond the originally claimed therapeutic framing (new indication, new patient group, or combination regimen).
Whether those filings overlap depends on:
- whether they use the same compound embodiments covered by EP1978015,
- whether they introduce a compound still inside the substituted imidazole definition,
- whether they use different indications that reframe the medical use claim elements.
How to read the “landscape” in Europe for this family
For EP families in Europe, the landscape analysis for an EP publication like EP1978015 is typically organized around three axes:
-
Family closure and legal status in EP-designated states
- Is the family granted in key territories (DE/FR/GB-like equivalents in EP practice, including IT/NL/SE, etc.)?
- Were claims amended during examination such that the final granted scope is narrower than the published one?
-
Claim-level overlap with closest-in-class compounds
- Identify whether the closest chemistry around the substituted imidazole scaffold keeps functional or substituent elements within the independent claim ranges.
-
Exclusivity tail
- Even if EP claims narrow, supplementary protection can extend market exclusivity through SPC where conditions are met. This tail often shapes entry timing more than marginal claim breadth.
What does the likely freedom-to-operate (FTO) picture look like in Europe?
Where infringement risk tends to concentrate
For this kind of EP compound/use package, infringement risk clusters at:
- Manufacture and supply of the covered substituted imidazole embodiments to generate directly infringing products.
- Sale and use of formulations that are “pharmaceutical compositions” containing a covered embodiment.
- Medical use where the administered active is within claim scope and the administration is for the claimed therapeutic condition.
Where design-arounds usually work
Competitors typically reduce risk by:
- moving outside the allowed substituent parameters on the imidazole core,
- switching to a different scaffold that avoids literal coverage,
- reframing to a different indication where the medical use claim elements are not met (subject to doctrine in EPC practice and how the claim is written).
What is the enforcement-relevant claim scope to focus on for diligence?
Key diligence checks for EP1978015
To evaluate whether EP1978015 remains a blocking asset in a target country, investors and R&D teams usually prioritize:
- Independent compound claim parameter list
Confirm every allowed substituent and linkage described in the Markush language, including any preferred lists.
- Dependent claim “trap” language
Determine if dependent claims effectively capture narrower forms that are commercially relevant (e.g., a specific salt form, a particular substituent that matches a marketed candidate).
- Medical use claim specificity
Identify the therapeutic condition wording and whether it is broad (class disease) or narrow (specific condition).
- Composition limitations
Check whether the composition claim requires particular excipients, dosing form types, or concentration ranges.
How does claim scope typically evolve from publication to grant in Europe?
European prosecution routinely results in:
- Markush narrowing to reduce novelty/inventive step attacks,
- clarification of substituent definitions (removal of ambiguous descriptors),
- tightening of therapeutic use language if prior art undermines breadth.
So, for an EP publication like EP1978015, the “real” landscape risk is the granted claims as enforced, not only the publication text.
Key Takeaways
- EP1978015 is a compound-centric European patent publication centered on substituted imidazole derivatives, with downstream protection for pharmaceutical compositions and medical use.
- The practical scope is driven by (i) the breadth of the substituted imidazole definitions in the independent compound claim and (ii) how specifically the medical use elements are written.
- Landscape collision in Europe typically occurs via later filings using the same core scaffold with different substituents, salt/polymorph follow-ons, and indication/combination use claims.
- Enforcement-relevant diligence focuses on the exact Markush substituent parameter list, the post-examination granted claim set, and the therapeutic use phrasing.
FAQs
1) Is EP1978015 primarily a “compound” patent or a “use” patent?
It is primarily structured as a compound patent with secondary coverage through composition and medical use claims.
2) What determines whether a competitor stays inside or outside EP1978015?
The determining factor is whether the competitor’s active ingredient stays within the substituent definitions of the independent compound claim, and whether the marketed administration matches the medical use wording.
3) Do dependent claims usually narrow to commercially relevant forms?
Yes. Dependent claims typically lock in narrower embodiments such as specific substituent selections, salt forms, or composition parameters that can align with development candidates.
4) Does the landscape depend on claim amendments during European prosecution?
Yes. The effective risk profile depends on the granted claim set in designated states, not only the original publication wording.
5) What are the most common competitor strategies around heterocycle EPs like this?
They usually shift substituents outside the Markush range, use alternate scaffolds, file follow-on patents for specific forms, or target different indications or combination regimens.
References
- European Patent Office. EP1978015 (publication).
- European Patent Office. European patent register for EP1978015 family and legal status.
